[go: up one dir, main page]

PE20091322A1 - Composicion farmaceutica antimalarica - Google Patents

Composicion farmaceutica antimalarica

Info

Publication number
PE20091322A1
PE20091322A1 PE2009000071A PE2009000071A PE20091322A1 PE 20091322 A1 PE20091322 A1 PE 20091322A1 PE 2009000071 A PE2009000071 A PE 2009000071A PE 2009000071 A PE2009000071 A PE 2009000071A PE 20091322 A1 PE20091322 A1 PE 20091322A1
Authority
PE
Peru
Prior art keywords
pharmaceutical composition
oil
antimalaric
chain triglycerides
triglycerides
Prior art date
Application number
PE2009000071A
Other languages
English (en)
Inventor
Clive Booles
Calvin John Ross
Martin James Sams
Original Assignee
Protopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protopharma Ltd filed Critical Protopharma Ltd
Publication of PE20091322A1 publication Critical patent/PE20091322A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/001—Particle size control
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/22—Valves or arrangement of valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mechanical Engineering (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) ARTEMETER O ARTEETER EN UNA CONCENTRACION DE 2-250 mg/g DE EXCIPIENTE; B) EXCIPIENTES FARMACEUTICAMENTE ACEPTABLES SELECCIONADOS DE TRIGLICERIDOS DE CADENA MEDIA, TRIGLICERIDOS DE CADENA CORTA, TRIGLICERIDOS MARINOS-OMEGA 3 Y ACEITE DE PESCADO. DICHA COMPOSICION FARMACEUTICA DE ADMINISTRACION SUBLINGUAL, BUCAL O NASAL ES ESENCIALMENTE LIBRE DE AGUA, ETANOL Y CONTIENE ADEMAS UN ACEITE ESENCIAL SELECCIONADO DE ACEITE DE LIMON, ACEITE DE CLAVO DE OLOR, ACEITE DE MENTA, ENTRE OTROS, SIENDO UTIL EN EL TRATAMIENTO DE MALARIA
PE2009000071A 2007-10-25 2009-01-21 Composicion farmaceutica antimalarica PE20091322A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0720967.9A GB0720967D0 (en) 2007-10-25 2007-10-25 Anti-material pharmaceutical composition
GBGB0806510.4A GB0806510D0 (en) 2007-10-25 2008-04-10 Anti-malarial pharmaceutical composition
GB0819559A GB2454567B (en) 2007-10-25 2008-10-27 Anti-malarial pharmaceutical composition

Publications (1)

Publication Number Publication Date
PE20091322A1 true PE20091322A1 (es) 2009-10-04

Family

ID=38829944

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000071A PE20091322A1 (es) 2007-10-25 2009-01-21 Composicion farmaceutica antimalarica

Country Status (25)

Country Link
US (5) US20110015260A1 (es)
EP (3) EP2749267A1 (es)
JP (2) JP5438018B2 (es)
CN (2) CN101835464B (es)
AP (2) AP2920A (es)
AU (1) AU2008315767B2 (es)
BR (2) BRPI0817833A8 (es)
CA (1) CA2702506C (es)
CY (1) CY1116759T1 (es)
DK (1) DK2209464T3 (es)
EA (2) EA017804B1 (es)
ES (2) ES2540727T3 (es)
GB (3) GB0720967D0 (es)
HR (1) HRP20140773T1 (es)
MX (1) MX2010004392A (es)
MY (2) MY153119A (es)
NZ (1) NZ584672A (es)
PE (1) PE20091322A1 (es)
PH (2) PH12010500880A1 (es)
PL (1) PL2209464T3 (es)
PT (1) PT2209464E (es)
RS (1) RS53507B1 (es)
SI (1) SI2209464T1 (es)
WO (1) WO2009053758A1 (es)
ZA (1) ZA201002607B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140256761A1 (en) * 2009-04-22 2014-09-11 Robert Lewis Steele Enhanced artemisinin-based combination therapy for treating parasitic mediated disease
GB2469791B (en) * 2009-04-23 2011-12-14 Londonpharma Ltd Transmucosal formulation of compounds providing dihydroartemesinin for use in the treatment of neoplastic disease
JP2012524771A (ja) * 2009-04-23 2012-10-18 ロンドンファーマ リミテッド 中性油を含む舌下用の医薬組成物
GB2469792A (en) * 2009-04-23 2010-11-03 Calvin John Ross Oil-based pharmaceutical formulation for sublingual delivery
US8290525B2 (en) 2010-01-15 2012-10-16 Comcast Cable Communications, Llc Text alternative to established voice call session
US8481757B2 (en) * 2010-02-04 2013-07-09 Georgua Tech Research Corporation Compounds and compositions useful in the treatment of malaria
US20140256762A1 (en) * 2012-07-06 2014-09-11 Robert Lewis Steele Artemisinin-based combination therapy for treating viral mediated disease
TWI733649B (zh) * 2014-03-07 2021-07-21 巴哈馬商克利普頓集團公司 用於治療寄生蟲介導疾病之強化的基於青蒿素組合療法
GB201414918D0 (en) * 2014-08-21 2014-10-08 Corbitt Terence Simon Formulations for transmucosal delivery
GB201414919D0 (en) * 2014-08-21 2014-10-08 Corbitt Terence Simon Formulations for transmucosal delivery
WO2016083827A1 (en) * 2014-11-27 2016-06-02 Cipla Limited Pharmaceutical composition comprising an artemisinin derivative for nasal or pulmonary delivery
US20220280734A1 (en) * 2021-03-07 2022-09-08 Sultan A. M. Daham Intaking an antiviral by inhalation or spraying for respiratory tract infection

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT84439B (pt) * 1986-03-10 1989-10-04 Burghart Kurt Processo de preparacao de composicoes farmaceuticas a base de nifedipina
US5057501A (en) * 1990-03-13 1991-10-15 Dermatologic Research Corporation Methods for treatment of papulosquamous and eczematous diseases
US20020099067A1 (en) * 1993-07-08 2002-07-25 Ulrich Posanski Pharmaceutical compositions for sparingly soluble therapeutic agents
US5578637A (en) * 1995-05-03 1996-11-26 University Of Washington Methods of inhibition or killing cancer cells using an endoperoxide
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US20050281752A1 (en) * 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20030082107A1 (en) * 1997-10-01 2003-05-01 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
CH692321A5 (de) * 1997-11-03 2002-05-15 Mepha Ag Pharmazeutisch wirksame Zusammensetzung, welche eine gegen Malariaparasiten wirksame Substanz enthält.
RU2129809C1 (ru) * 1998-04-24 1999-05-10 Захарчук Анатолий Васильевич Способ получения пищевого продукта в капсулах
CN1084333C (zh) * 1998-06-17 2002-05-08 中国科学院上海药物研究所 新的青蒿素化合物,其制备方法以及含有它们的药物组合物
KR100640113B1 (ko) * 1998-07-14 2006-10-31 바이엘 악티엔게젤샤프트 구충제 아르테미시닌 유도체(엔도퍼옥시드)
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
ES2153786B1 (es) * 1999-06-10 2001-10-16 S A L V A T Lab Sa Composicion farmaceutica liquida para la administracion oral de principios activos amargos y susceptibles de hidrolisis.
FR2796276B1 (fr) * 1999-07-15 2003-05-16 Oreal Composition sous forme solide comprenant une huile et un compose gelifiant particulier, procede de traitement cosmetique et utilisation dudit compose
US6617356B2 (en) * 2000-01-03 2003-09-09 Naturally Scientific Inc Gel system for oral and topical administration of water insoluble and/or water intolerant drugs and supplements
JP3752127B2 (ja) * 2000-03-21 2006-03-08 花王株式会社 油脂組成物
CA2415470A1 (en) * 2000-06-02 2001-12-06 Jerzy Zawistowski Oil compositions comprising short, medium and long chain triglycerides and use thereof in reducing weight gain
US20040038933A1 (en) * 2000-10-20 2004-02-26 Yutaro Kaneko Pharmaceutical compositions, dose and method for treating malaria
US6951846B2 (en) * 2002-03-07 2005-10-04 The United States Of America As Represented By The Secretary Of The Army Artemisinins with improved stability and bioavailability for therapeutic drug development and application
CA2507522C (en) * 2002-12-13 2015-02-24 Durect Corporation Oral drug delivery system
JP2004307428A (ja) * 2003-04-10 2004-11-04 Porien Project Kk 原虫感染症予防治療薬
US20050042281A1 (en) * 2003-08-21 2005-02-24 Singh Nikhilesh N. Compositions for delivering therapeutic agents across the oral mucosa
CN101005828B (zh) * 2004-06-17 2012-01-11 维尔恩公司 用于经粘膜递送活性成分的包含粘膜粘附蛋白和所述活性物质的组合物
CN1650854A (zh) * 2004-12-08 2005-08-10 广州中生生物技术有限公司 一种含有蒿甲醚（或蒿乙醚或蒿琥酯）微乳剂的制备工艺
US20060233895A1 (en) * 2005-04-15 2006-10-19 Brown Paul R Herbal remedy for treating Lyme disease
BRPI0611272A2 (pt) * 2005-05-03 2011-11-16 Mutual Pharmaceutical Co formulações de quinina
SI1933809T1 (sl) * 2005-10-11 2012-08-31 Yissum Res Dev Co Sestavki za mazalno dajanje
EP1976521B1 (en) * 2006-01-25 2015-03-11 Insys Therapeutics, Inc. Sublingual fentanyl spray
CN101310720A (zh) * 2007-05-22 2008-11-26 天津丹溪国药研究所 一种治疗疟疾的蒿甲醚滴丸剂的制备方法
CN101317839A (zh) * 2007-06-05 2008-12-10 天津丹溪国药研究所 一种治疗疟疾的复方蒿甲醚滴丸剂的制备方法
JP2012524771A (ja) * 2009-04-23 2012-10-18 ロンドンファーマ リミテッド 中性油を含む舌下用の医薬組成物
MX2011010961A (es) * 2009-04-23 2012-04-20 Londonpharma Ltd Formula en aspersion sublingual que comprende dihidroartemesinina.
GB2481728B (en) * 2010-06-30 2012-05-23 Londonpharma Ltd Formulations and delivery devices for the sublingual administration of opioids

Also Published As

Publication number Publication date
EP2209464A1 (en) 2010-07-28
EP2749267A1 (en) 2014-07-02
EA017804B1 (ru) 2013-03-29
AP2010005231A0 (en) 2010-04-30
CA2702506C (en) 2015-08-25
GB2454567B (en) 2010-06-30
EP2653153A1 (en) 2013-10-23
US20180071207A1 (en) 2018-03-15
PH12010500880A1 (es) 2014-10-07
BRPI0817833A2 (pt) 2015-03-31
US20110015260A1 (en) 2011-01-20
ZA201002607B (en) 2011-10-26
ES2494340T3 (es) 2014-09-15
PH12013501567B1 (en) 2014-10-08
EP2209464B1 (en) 2014-06-04
AU2008315767B2 (en) 2013-11-07
CN103622950A (zh) 2014-03-12
JP2011500781A (ja) 2011-01-06
CN101835464B (zh) 2013-05-15
CY1116759T1 (el) 2017-03-15
EA026281B1 (ru) 2017-03-31
HRP20140773T1 (hr) 2014-11-07
MY153119A (en) 2014-12-31
NZ584672A (en) 2012-03-30
AP2013006997A0 (en) 2013-07-31
MX2010004392A (es) 2010-06-25
US20190290576A1 (en) 2019-09-26
US20140179772A1 (en) 2014-06-26
ES2540727T3 (es) 2015-07-13
US20160038404A1 (en) 2016-02-11
PH12013501567A1 (en) 2014-10-08
JP2014088400A (ja) 2014-05-15
CN101835464A (zh) 2010-09-15
PL2209464T3 (pl) 2014-11-28
AP2920A (en) 2014-05-31
BRPI0817833A8 (pt) 2015-09-15
EP2653153B1 (en) 2015-05-27
BR122013005952A2 (pt) 2015-07-14
AU2008315767A1 (en) 2009-04-30
MY161745A (en) 2017-05-15
WO2009053758A1 (en) 2009-04-30
AP3542A (en) 2016-01-13
SI2209464T1 (sl) 2014-11-28
GB0720967D0 (en) 2007-12-05
HK1190645A1 (zh) 2014-07-11
GB2454567A (en) 2009-05-13
RS53507B1 (sr) 2015-02-27
GB0806510D0 (en) 2008-05-14
PT2209464E (pt) 2014-09-05
EA201000497A1 (ru) 2010-12-30
JP5438018B2 (ja) 2014-03-12
CN103622950B (zh) 2016-05-04
EA201300151A1 (ru) 2013-10-30
DK2209464T3 (da) 2014-08-25
GB0819559D0 (en) 2008-12-03
CA2702506A1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
PE20091322A1 (es) Composicion farmaceutica antimalarica
ES2553742T3 (es) Forma de dosificación farmacéutica que comprende 6'-fluor-(N-metil- o N,N-dimetil)-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina
EA200801602A1 (ru) Эмульсия
ES2916604T1 (es) Ensayos de detección de nrf2 y métodos y composiciones relacionados
FI3782612T3 (fi) Sytidiinianalogien oraalisia formulaatioita ja menetelmiä niiden käyttämiseksi
ECSP13012423A (es) FORMA DE DOSIFICACION FARMACEUTICA QUE COMPRENDE 6'-FLUORO-(N-METIL- O N,N-DIMETIL)-4-FENIL-4',9'-DIHIDRO-3'H-ESPIRO[CICLOHEXAN-1,1'-PIRANO[3,4,b]INDOL]-4-AMINA PARA EL TRATAMIENTO DE DOLOR NEUROPATICO
CL2011002858A1 (es) Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor.
CL2007003604A1 (es) Composicion farmaceutica para administrar oral que comprende el compuesto 17-aminogeldanamicina amorfo; y su uso en el tratamiento del cancer.
BR112012007412A2 (pt) tabletes transformáveis de forma oral.
CU20080235A7 (es) Composiciones farmacéuticas estabilizadas que comprenden fesoterodina
AR060931A1 (es) Producto farmaceutico recubierto para la administracion intraoral de nicotina y su uso y elaboracion
CO6400186A2 (es) Tabletas de acetato de ulipristal
MX2012013212A (es) Forma farmaceutica oral resistente al alcohol.
WO2007143155A3 (en) Sustained release pharmaceutical dosage form containing phenylephrine
BRPI0713306A8 (pt) Composição farmacêutica compreendendo amlodipina e losartan
PE20081799A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
NO20090605L (no) Metode for inhibering av respirasjonsdepresjon ved bruk av positive allosteriske AMPA reseptormodulatorer
NO20084998L (no) Tolags tablett for a avverge kardiovaskulaere folger
CO6321158A2 (es) Formulacion oral
PE20081106A1 (es) Comprimidos pediatricos de capecitabina
ATE499939T1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
AR046036A1 (es) Composiciones de risedronato y metodos para su uso
PE20120956A1 (es) Composicion farmaceutica que contiene buprenorfina y nalmefeno
AR030630A1 (es) Composiciones farmaceuticas
AR066666A1 (es) Composicion farmaceutica que comprende la combinacion de un agente antiinflamatorio no esteroideo y un agente anticonvulsivante

Legal Events

Date Code Title Description
FG Grant, registration